English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, July 1, 2021
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong
Wednesday, June 30, 2021
エーザイ、自社創製の新規不眠症治療薬「DAYVIGO(R)」(一般名:レンボレキサント)を香港において新発売
Thursday, June 24, 2021
エーザイとバイオジェン、lecanemabがアルツハイマー病治療を対象として米国FDAよりブレイクスルーセラピーに指定
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)
エーザイ、抗がん剤「タズベリク(R)錠200mg」について日本においてEZH2遺伝子変異陽性の濾胞性リンパ腫に係る効能効果で製造販売承認を取得
Wednesday, June 23, 2021
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma
Friday, June 18, 2021
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
エーザイとブリストル マイヤーズ スクイブ、エーザイ創製の抗体薬物複合体MORAb-202に関するグローバルな戦略的提携契約を締結
Tuesday, June 15, 2021
エーザイ、「Zonegran(R)」の欧州およびその他の地域の権利をAdvanz Pharma社に譲渡
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575